CHEK vs GXAI vs CLOV vs AEYE vs AEMD

For growth investors, Gaxos.

ai Inc. (GXAI) is the stronger pick with 1473% revenue growth year-over-year, versus 14. 5% for AudioEye, Inc. (AEYE). Analysts rate Clover Health Investments, Corp. (CLOV) a "Hold" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AudioEye, Inc.

(AEYE) delivered a total return of -67. 2%, compared to -99. 8% for Aethlon Medical, Inc. (AEMD). Over 10 years, the gap is even starker: AEYE returned +80. 2% versus AEMD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Gaxos.

ai Inc. (GXAI) is the lower-risk stock at 0. 53β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 332% more volatile than GXAI relative to the S&P 500. On balance sheet safety, Aethlon Medical, Inc. (AEMD) carries a lower debt/equity ratio of 13% versus 15% for AudioEye, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gaxos.

ai Inc. (GXAI) is pulling ahead at 1473% versus 14. 5% for AudioEye, Inc. (AEYE). On earnings-per-share growth, the picture is similar: Gaxos. ai Inc. grew EPS 52. 0% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, CLOV leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Check-Cap Ltd.

(CHEK) is the more profitable company, earning 0. 0% net margin versus -850. 3% for Gaxos. ai Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CHEK leads at 0. 0% versus -919. 7% for GXAI. At the gross margin level — before operating expenses — CLOV leads at 103. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Gaxos.

ai Inc. (GXAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 53)). AudioEye, Inc. (AEYE) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GXAI: -97. 5%, AEYE: +80. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CHEK (Healthcare) and GXAI (Technology) and CLOV (Healthcare) and AEYE (Technology) and AEMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CHEK is a small-cap quality compounder stock; GXAI is a small-cap high-growth stock; CLOV is a small-cap high-growth stock; AEYE is a small-cap quality compounder stock; AEMD is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.